Meredith Hackel

American Veterinary Medical Association — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

39h-index5.5kcitations188works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antibiotic Resistance in Bacteria(148), Antibiotics Pharmacokinetics and Efficacy(81), Antibiotic Use and Resistance(76), Bacterial Identification and Susceptibility Testing(35), Pharmaceutical and Antibiotic Environmental Impacts(33)

Publications188 total

P-1339. In vitro activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa collected worldwide stratified by age group, ATLAS Global Surveillance Program, 2019-2023
Open Forum Infectious Diseases·2026Open Access
P-1338. In vitro activity of ceftazidime-avibactam and comparator agents against Pseudomonas aeruginosa stratified by infection source and ward: ATLAS Global Surveillance Program, 2019-2023
Open Forum Infectious Diseases·2026Open Access
P-1207. In Vitro Activity of Zoliflodacin against Neisseria gonorrhoeae Isolates Collected in 2022 from The United States
Open Forum Infectious Diseases·2026Open Access
P-1156. In Vitro Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Gram-negative Isolates from a Global Collection, 2018-2023
Open Forum Infectious Diseases·2026Open Access
P-1157. In Vitro Antimicrobial Activity of Cefepime-Taniborbactam Against Molecularly Characterized Enterobacterales and P. aeruginosa Collected Worldwide from 2018-2023
Open Forum Infectious Diseases·2026Open Access
Performance evaluation of plazomicin susceptibility testing of Enterobacterales on VITEK 2 and VITEK 2 Compact Systems
Journal of Clinical Microbiology·2025Open Access
<i>In vitro</i> activity of gepotidacin against urinary tract infection isolates of Enterobacterales, <i>Enterococcus faecalis</i> , and <i>Staphylococcus saprophyticus</i>
Antimicrobial Agents and Chemotherapy·2025· 1 citedOpen Access
Author Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
Nature Communications·2025· 1 citedOpen Access
P-1521. Susceptibility of Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> (CRPA) With and Without Carbapenemases to Cefepime-Taniborbactam and Comparators: GEARS Antimicrobial Surveillance Program, United States, 2018-2022
Open Forum Infectious Diseases·2025Open Access
P-1514. Cefepime-taniborbactam Exhibits Limited Cross-resistance with Ceftazidime-avibactam and Ceftolozane-tazobactam against Carbapenem-nonsusceptible Enterobacterales and Multidrug-resistant <i>Pseudomonas aeruginosa</i> from the United States 2018-2022
Open Forum Infectious Diseases·2025Open Access
P-2102. Performance of the VITEK®2 Advanced Expert System (AES) as a Rapid Aid for Reporting Antimicrobial Susceptibility Testing in <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter</i> spp
Open Forum Infectious Diseases·2025· 1 citedOpen Access
P-1513. <i>In Vitro</i> Activity of Ceftaroline against Bacterial Pathogens from Pediatric Patients Collected During the ATLAS Global Surveillance Program in 2018-2022
Open Forum Infectious Diseases·2025Open Access
Author Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
Nature Communications·2025Open Access
In Vitro Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenemase-producing Enterobacterales Collected in Turkey and the Middle East as Part of the ATLAS Surveillance Program: 2018-2022
Journal of Global Antimicrobial Resistance·2024· 1 citedOpen Access
Susceptibility of Enterobacterales Collected in the Middle East and Turkey to Aztreonam/Avibactam and Comparator Agents Stratified by Infection Source: ATLAS Surveillance Program 2018-2022
Journal of Global Antimicrobial Resistance·2024Open Access
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
Nature Communications·2024· 14 citedOpen Access
Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and <i>Pseudomonas aeruginosa</i>: GEARS global surveillance programme 2018–22
Journal of Antimicrobial Chemotherapy·2024· 19 citedOpen Access
2150. <i>In Vitro</i> Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> (CRPA) from the United States, 2018-2021
Open Forum Infectious Diseases·2023· 1 citedOpen Access
2127. <i>In vitro</i> Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Frequently Causing Community-Acquired Respiratory Tract Infections in Patients from a Global Population: ATLAS Surveillance Program 2018-2021
Open Forum Infectious Diseases·2023Open Access
2129. Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Isolates from the United States 2018-2021
Open Forum Infectious Diseases·2023Open Access
page 1 of 10Next →

Frequent Co-authors

Daniel F. Sahm(19), Robert E. Badal(17), Daryl J. Hoban(17), Samuel K. Bouchillon(14), Krystyna M. Kazmierczak(13), Douglas J. Biedenbach(12), Stephen Hawser(11), James A. Karlowsky(11), Sibylle Lob(9), S. Bouchillon(7), Yoshinori Yamano(7), Christine Lascols(7), Patricia A. Bradford(6), Masakatsu Tsuji(5), Roger Echols(5), Paul G. Higgins(3), Mark G. Wise(3), Boudewijn L. M. de Jonge(3), Gisele Peirano(3), Johann Pitout(3)